Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 23.

Peters, Solange; Dafni, Urania; Boyer, Michael; De Ruysscher, Dirk; Faivre-Finn, Corinne; Felip, Enriqueta; Garrido, Pilar; Girard, Nicolas; Guckenberger, Matthias; Haanen, John; Le Pechoux, Cecile; Mornex, Francoise; Ozsahin, Mahmut; Paz-Ares, Luis; Planchard, David; Raben, David; Ramalingam, Suresh; Reck, Martin; Smit, Egbert; Stahel, Rolf; Stenzinger, Albrecht; Swanton, Charlie; Vallone, Stefania; Garassino, Marina (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 30(2):161-165.

Peters, Solange; Stahel, Rolf; Bubendorf, Lukas; Bonomi, Philip; Villegas, Augusto; Kowalski, Dariusz M; Baik, Christina S; Isla, Dolores; Carpeno, Javier De Castro; Garrido, Pilar; Rittmeyer, Achim; Tiseo, Marcello; Meyenberg, Christoph; de Haas, Sanne; Lam, Lisa H; Lu, Michael W; Stinchcombe, Thomas E (2019). Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clinical Cancer Research, 25(1):64-72.

Früh, Martin; Betticher, Daniel C; Stupp, Roger; Xyrafas, Alexandros; Peters, Solange; Ris, Hans Beat; Mirimanoff, Rene Olivier; Ochsenbein, Adrian F; Schmid, Ralph; Matzinger, Oscar; Stahel, Rolf A; Weder, Walter; Guckenberger, Matthias; Rothschild, Sacha I; Lardinois, Didier; Mach, Nicholas; Mark, Michael; Gautschi, Oliver; Thierstein, Sandra; Biaggi Rudolf, Christine; Pless, Miklos (2019). Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). Journal of Thoracic Oncology, 14(1):115-123.

Rulle, Undine; Tsourti, Zoi; Casanova, Ruben; Deml, Karl-Friedrich; Verbeken, Eric; Thunnissen, Erik; Warth, Arne; Cheney, Richard; Sejda, Aleksandra; Speel, Ernst Jan; Madsen, Line Bille; Nonaka, Daisuke; Navarro, Atilio; Sansano, Irene; Marchetti, Antonio; Finn, Stephen P; Monkhorst, Kim; Kerr, Keith M; Haberecker, Martina; Wu, Chengguang; Zygoura, Panagiota; Kammler, Roswitha; Geiger, Thomas; Gendreau, Steven; Schulze, Katja; Vrugt, Bart; Wild, Peter; Moch, Holger; Weder, Walter; Ciftlik, Ata Tuna; Dafni, Urania; Peters, Solange; Bubendorf, Lukas; Stahel, Rolf; Soltermann, Alex (2018). Computer-based intensity measurement assists pathologists in scoring PTEN immunohistochemistry - Clinical associations in NSCLC patients of the ETOP Lungscape cohort. Journal of Thoracic Oncology, 13(12):1851-1863.

Peters, Solange; Curioni-Fontecedro, Alessandra; Nechushtan, Hovav; Shih, Jin-Yuan; Liao, Wei-Yu; Gautschi, Oliver; Spataro, Vito; Unk, Mojca; Chih-Hsin Yang, James; Lorence, Robert M; Carrière, Philippe; Cseh, Agnieszka; Chang, Gee-Chen (2018). Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. Journal of Thoracic Oncology, 13(12):1897-1905.

Peters, Solange; Kerr, Keith M; Stahel, Rolf (2018). PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treatment Reviews, 62:39-49.

Rosell, Rafael; Dafni, Urania; Felip, Enriqueta; Curioni-Fontecedro, Alessandra; Gautschi, Oliver; Peters, Solange; Massutí, Bartomeu; Palmero, Ramon; Aix, Santiago Ponce; Carcereny, Enric; Früh, Martin; Pless, Miklos; Popat, Sanjay; Kotsakis, Athanasios; Cuffe, Sinead; Bidoli, Paolo; Favaretto, Adolfo; Froesch, Patrizia; Reguart, Noemí; Puente, Javier; Coate, Linda; Barlesi, Fabrice; Rauch, Daniel; Thomas, Michael; Camps, Carlos; Gómez-Codina, Jose; Majem, Margarita; Porta, Rut; Shah, Riyaz; Hanrahan, Emer; et al (2017). Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respiratory Medicine, 5(5):435-444.

Gautschi, Oliver; Rothschild, Sacha I; Li, Qiyu; Matter-Walstra, Klazien; Zippelius, Alfred; Betticher, Daniel C; Früh, Martin; Stahel, Rolf A; Cathomas, Richard; Rauch, Daniel; Pless, Miklos; Peters, Solange; Froesch, Patrizia; Zander, Thilo; Schneider, Martina; Biaggi, Christine; Mach, Nicolas; Ochsenbein, Adrian F; Swiss Group for Clinical Cancer Research (SAKK) (2017). Bevacizumab plus pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous non-small-cell lung cancer: Update from the swiss group for clinical cancer research (SAKK) 19/09 trial. Clinical Lung Cancer, 18(3):303-309.

Bubendorf, Lukas; Dafni, Urania; Schöbel, Martin; Finn, Stephen P; Tischler, Verena; Sejda, Aleksandra; Marchetti, Antonio; Thunnissen, Erik; Verbeken, Eric K; Warth, Arne; Sansano, Irene; Cheney, Richard; Speel, Ernst Jan M; Nonaka, Daisuke; Monkhorst, Kim; Hager, Henrik; Martorell, Miguel; Savic, Spasenija; Kerr, Keith M; Tan, Qiang; Tsourti, Zoi; Geiger, Thomas R; Kammler, Roswitha; Schulze, Katja; Das-Gupta, Ashis; Shames, David; Peters, Solange; Stahel, Rolf A (2017). Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer, 111:143-149.

Peters, Solange; Stahel, Rolf A; Dafni, Urania; Aix, Santiago Ponce; Massutí, Bartomeu; Gautschi, Oliver; Coate, Linda; López Martín, Ana; van Heemst, Robbert; Berghmans, Thierry; Meldgaard, Peter; Cobo Dols, Manuel; Noguera, Javier Garde; Curioni-Fontecedro, Alessandra; Rauch, Daniel; Mark, Michael T; Cuffe, Sinead; Biesma, Bonne; van Henten, Arjen Mj; Vidal, Óscar Juan; Sanchez, Ramón Palmero; Villa Guzmán, José Carlos; Martin, Ricardo Collado; Peralta, Sergio; Insa, Amelia; Summers, Yvonne; Láng, István; Horgan, Anne; Ciardiello, Fortunato; de Hosson, Sander; et al (2017). Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung trial. Journal of Thoracic Oncology, 12(4):752-762.

Tabernero, Josep; Vyas, Malvika; Giuliani, Rosa; Arnold, Dirk; Cardoso, Fatima; Casali, Paolo G; Cervantes, Andres; Eggermont, Alexander Mm; Eniu, Alexandru; Jassem, Jacek; Pentheroudakis, George; Peters, Solange; Rauh, Stefan; Zielinski, Christoph C; Stahel, Rolf A; Voest, Emile; Douillard, Jean-Yves; McGregor, Keith; Ciardiello, Fortunato (2016). Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open, 1(6):e000142.

Stahel, Rolf A; Riesterer, Oliver; Xyrafas, Alexandros; Opitz, Isabelle; Beyeler, Michael; Ochsenbein, Adrian; Früh, Martin; Cathomas, Richard; Nackaerts, Kristiaan; Peters, Solange; Mamot, Christoph; Zippelius, Alfred; Mordasini, Carlo; Caspar, Clemens B; Eckhardt, Katrin; Schmid, Ralph A; Aebersold, Daniel M; Gautschi, Oliver; Nagel, Wolfgang; Töpfer, Michael; Krayenbuehl, Jerome; Ribi, Karin; Ciernik, Llja F; Weder, Walter (2015). Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncology, 16(16):1651-1658.

Gautschi, Oliver; Milia, Julie; Cabarrou, Bastien; Bluthgen, Marie-Virginia; Besse, Benjamin; Smit, Egbert F; Wolf, Juergen; Peters, Solange; Früh, Martin; Koeberle, Dieter; Oulkhouir, Youssouf; Schuler, Martin; Curioni-Fontecedro, Alessandra; Huret, Benjamin; Kerjouan, Mallorie; Michels, Sebastian; Pall, Georg; Rothschild, Sacha; Schmid-Bindert, Gerald; Scheffler, Matthias; Veillon, Rémi; Wannesson, Luciano; Diebold, Joachim; Zalcman, Gérard; Filleron, Thomas; Mazières, Julien (2015). Targeted therapy for patients with BRAF-mutant lung cancer: results from the european EURAF cohort. Journal of Thoracic Oncology, 10(10):1451-1457.

Gautschi, Oliver; Mach, Nicholas; Rothschild, Sacha I; Li, Qiyu; Stahel, Rolf A; Zippelius, Alfred; Cathomas, Richard; Früh, Martin; Betticher, Daniel C; Peters, Solange; Rauch, Daniel; Feilchenfeldt, Jonas; Bubendorf, Lukas; Savic, Spasenija; Jaggi, Rolf; Leibundgut, Elisabeth Oppliger; Largiadèr, Carlo; Brutsche, Martin; Pilop, Christiane; Stalder, Lukas; Pless, Miklos; Ochsenbein, Adrian F (2015). Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical Lung Cancer, 16(5):358-365.

Pless, Miklos; Stupp, Roger; Ris, Hans-Beat; Stahel, Rolf A; Weder, Walter; Thierstein, Sandra; Gerard, Marie-Aline; Xyrafas, Alexandros; Früh, Martin; Cathomas, Richard; Zippelius, Alfred; Roth, Arnaud; Bijelovic, Milorad; Ochsenbein, Adrian; Meier, Urs R; Mamot, Christoph; Rauch, Daniel; Gautschi, Oliver; Betticher, Daniel C; Mirimanoff, René-Olivier; Peters, Solange (2015). Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet, 386(9998):1049-1056.

Peters, Solange; Weder, Walter; Dafni, Urania; Kerr, Keith M; Bubendorf, Lukas; Meldgaard, Peter; O'Byrne, Kenneth J; Wrona, Anna; Vansteenkiste, Johan; Felip, Enriqueta; Marchetti, Antonio; Savic, Spasenija; Lu, Shun; Smit, Egbert; Dingemans, Anne-Marie; Blackhall, Fiona H; Baas, Paul; Camps, Carlos; Rosell, Rafael; Stahel, Rolf A (2014). Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. Journal of Thoracic Oncology, 9(11):1675-1684.

Blackhall, Fiona H; Peters, Solange; Bubendorf, Lukas; Dafni, Urania; Kerr, Keith M; Hager, Henrik; Soltermann, Alex; O'Byrne, Kenneth J; Dooms, Christoph; Sejda, Aleksandra; Hernández-Losa, Javier; Marchetti, Antonio; Savic, Spasenija; Tan, Qiang; Thunnissen, Erik; Speel, Ernst-Jan M; Cheney, Richard; Nonaka, Daisuke; de Jong, Jeroen; Martorell, Miguel; Letovanec, Igor; Rosell, Rafael; Stahel, Rolf A (2014). Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology, 32(25):2780-2787.

Peters, Solange; Stahel, R A (2014). Successes and limitations of targeted cancer therapy. Basel: Karger.

Stahel, Rolf; Peters, Solange; Baas, Paul; Brambilla, Elisabeth; Cappuzzo, Federico; De Ruysscher, Dirk; Eberhardt, Wilfried Ernst Erich; Felip, Enriqueta; Fennell, Dean; Marchetti, Antonio; Paz-Ares, Luis; Adjei, Alex A (2013). Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer, 82(3):375-382.

Peters, Solange; Taron, Miquel; Bubendorf, Lukas; Blackhall, Fiona; Stahel, Rolf (2013). Treatment and detection of ALK-rearranged NSCLC. Lung Cancer, 81(2):145-154.

Lee, James A; Bubendorf, Lukas; Stahel, Rolf; Peters, Solange (2013). Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives. Expert Review of Anticancer Therapy, 13(5):625-36.

Demierre, Nadine; Zoete, Vincent; Michielin, Olivier; Stauffer, Edouard; Zimmermann, Dieter R; Betticher, Daniel C; Peters, Solange (2013). A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable? Lung Cancer, 80(1):81-84.

Gautschi, Oliver; Dingemans, Anne-Marie; Crowe, Susanne; Peters, Solange; Roder, Heinrich; Grigorieva, Julia; Roder, Joanna; Zappa, Francesco; Pless, Miklos; Brutsche, Martin; Baty, Florent; Bubendorf, Lukas; Hsu Schmitz, Shu-Fang; Na, Kyung-Jae; Carbone, David; Stahel, Rolf; Smit, Egbert (2013). VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer, 79(1):59-64.

This list was generated on Thu Jun 20 21:06:07 2019 CEST.